HMGB1 Attenuates Anti-Metastatic Defense of the Lymph Nodes in Colorectal Cancer

Moriwaka, Yukiko; Luo, Yi; Ohmori, Hitoshi; Fujii, Kenichi; Tatsumoto, Nobuhide; Sasahira, Tomonori; Kuniyasu, Hiroki

doi:10.1159/000272950

Cited by 27 publications

(22 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…HMGB1 binds to the endogenous receptor for advanced glycation endproducts [7], exogenous toll-like receptor 2/4/9 (TLR2/4/9) [8,9], and CD24/Siglec-10 [10], and induces the expression of proinammatory cytokines, chemokines, and adhesion molecules [3,6]. Although, HMGB1 was initially thought to be a late mediator of sepsis, recent data also indicated that HMGB1 is associated with many other pathological conditions, such as autoimmune disease [11], cancer [12][13][14], trauma, ischemia-reperfusion injury [15,16], tissue repair and regeneration [17,18], and cardiovascular diseases [19]. Furthermore, HMGB1 has restorative effects on CD4 1 T-helper cell modulation [20].…”

Section: Introductionmentioning

confidence: 99%

“…thought to be a late mediator of sepsis, recent data also indicated that HMGB1 is associated with many other pathological conditions, such as autoimmune disease [11], cancer [12][13][14], trauma, ischemia-reperfusion injury [15,16], tissue repair and regeneration [17,18], and cardiovascular diseases [19]. Furthermore, HMGB1 has restorative effects on CD4 1 T-helper cell modulation [20].…”

mentioning

confidence: 99%

See 1 more Smart Citation

HMGB1 blockade attenuates experimental autoimmune myocarditis and suppresses Th17‐cell expansion

Sun

Zhou

et al. 2011

Eur J Immunol

View full text Add to dashboard Cite

High-mobility group box 1 (HMGB1), a non-histone nuclear protein, has been implicated in cardiovascular diseases. Dilated cardiomyopathy (DCM), one of the leading causes of heart failure, is often caused by coxsackievirus B3-triggered myocarditis and promoted by the post-infectious autoimmune process. Th17 cells, a novel CD4 1 T subset, may be important in the pathogenesis of autoimmune myocarditis. In the present study, we attempted to block HMGB1 function with a monoclonal antibody specific for HMGB1 B box and investigated the effects of the blockade on Th17 cells and experimental autoimmune myocarditis (EAM). After induction of EAM, HMGB1 protein levels were significantly elevated both in the heart and blood. Administration of an anti-HMGB1 B box mAb attenuated cardiac pathological changes and reduced the number of infiltrating inflammatory cells in the heart during EAM. These protective effects of HMGB1 blockade correlated with a reduced number of Th17 cells in local tissues and lower levels of IL-17 in the serum. Furthermore, in vitro, studies demonstrated that HMGB1 promoted Th17-cell expansion. Therefore, we speculate that HMGB1 blockade ameliorates cardiac pathological changes in EAM by suppressing Th17 cells.Key words: Dilated cardiomyopathy . Experimental myocarditis . HMGB1 . Th17 cells IntroductionHigh-mobility group box 1 (HMGB1), a non-histone nuclear protein, has been functionally characterized as an alarmin or damage-associated molecular pattern (DAMP) [1,2]. It is constitutively expressed in quiescent cells and stored in the nucleus [3]. HMGB1 is one of the most evolutionarily conserved proteins in eukaryotes, with 100% identity between mice and rats, and 99% identity between rodents and humans [3].HMGB1 has been shown to be involved in both infectious and non-infectious inflammatory disease [2,4]. HMGB1 is released into the extracellular milieu during cell apoptosis/death [5], and by macrophages and monocytes in response to cellular stress or injury [6]. HMGB1 binds to the endogenous receptor for advanced glycation endproducts [7], exogenous toll-like receptor 2/4/9 (TLR2/4/9) [8,9], and CD24/Siglec-10 [10], and induces the expression of proinammatory cytokines, chemokines, and adhesion molecules [3,6]. Although, HMGB1 was initially 3586thought to be a late mediator of sepsis, recent data also indicated that HMGB1 is associated with many other pathological conditions, such as autoimmune disease [11], cancer [12][13][14], trauma, ischemia-reperfusion injury [15,16], tissue repair and regeneration [17,18], and cardiovascular diseases [19]. Furthermore, HMGB1 has restorative effects on CD4 1 T-helper cell modulation [20].Dilated cardiomyopathy (DCM) is one of the leading causes of severe heart failure and the most common indication for heart transplantation. DCM is often caused by coxsackievirus B3-triggered myocarditis [21]. Experimental autoimmune myocarditis (EAM) is a mouse model of postinfectious myocarditis, characterized by inflammatory infiltration of the myocardium and cardiac myocyte ne...

show abstract

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

HMGB1 blockade attenuates experimental autoimmune myocarditis and suppresses Th17‐cell expansion

Sun

Zhou

et al. 2011

Eur J Immunol

View full text Add to dashboard Cite

show abstract

“…In recent years, an increasing number of oncogenes related to the incidence, invasion, and metastasis of cervical cancer have been discovered, such as P53, bcl-2, survin, HPV E6 and E7 [6,7] . HMGB1 was discovered as a multifunctional cytokine involved in the growth, invasion, metastasis, clinical stage and prognosis of pancreatic cancer [8] , liver cancer, gastric cancer, melanoma, colon cancer [9] , breast cancer, bile duct cancer, and prostate cancer. Our early experiments demonstrated that HMGB1 protein in cervical squamous cell carcinoma (CSCC) especially in metastatic tissues was a strongly positive expression.…”

Section: Discussionmentioning

confidence: 99%

Effects of HMGB1 expression suppressed by siRNA on cell cycle and proliferation of human cervical cancer cell line HeLa

Qiu

Wang

Qin

2010

Clin. Oncol. Cancer Res.

View full text Add to dashboard Cite

OBJECTIVEIn this study, RNA interference was used to evaluate the effects of HMGB1 expression on cell cycle and proliferation of the human cervical cancer cell line HeLa. METHODSWe had previously constructed and screened effective eukaryotic expression vectors carrying PGCsi3.0-1/ HMGB1 siRNA and PGCsi3.0-3/HMGB1 siRNA, then the vectors were transfected into HeLa cells. The expression of HMGB1 before and after transfection in HeLa cells were detected by RT-PCR and Western blot. The cell viability and proliferating activity was tested by Trypan blue dye test and MTT, and the cell cycle was determined by fl ow cytometry. RESULTS The introduction of PGCsi3.0-1/HMGB1 siRNA and PGCsi3.0-3/HMGB1 siRNA inhibited the expression of HMGB1 mRNA and protein efficiently and specifically, there was a signifi cant diff erence between the siRNA groups and the control groups P < 0.05). The proliferation speed of PGCsi3.0-1 group and PGC si3.0-3 group were obviously slower than those of PGCsi3.0-Neg group and non-transfected group. Flow cytometry showed that the content of DNA in G2 phase in PGCsi3.0-1 group and PGCsi3.0-3 group were obviously more than those in PGCsi3.0-Neg group and non-transfected group, but the content in S phase was less (P < 0.01). The progression of cell cycle was arrested from G2 to S phase. CONCLUSION PGCsi3.0-1/HMGB1 siRNA and PGCsi3.0-3/ HMGB1 siRNA could specially suppress the expression of HMGB1 gene, inhibit the proliferation speed of HeLa cells effectively, and arrest the progression of cell cycle from G2 to S phase. RNAi provides a new approach to the bio-therapy of cervical cancer.

show abstract

“…E-Selektin, selbst ein wichtiger Faktor bei der Metastasierung, scheint die zellul ä re Expression von HMGB1 im kolorektalen Karzinom zu drosseln, f ü hrt andererseits aber zu vermehrter HMGB1-Freisetzung in das extrazellul ä re Milieu, wo HMGB1 die vermehrte Expression von E-Selektin im Sinne eines positiven Feedback-Mechanismus f ö rdert [111] . Dar ü ber hinaus f ü hrt die Freisetzung von HMGB1 aus kolorektalen Tumorzellen zur Abnahme der Makrophagenzahlen in benachbarten, befallenen wie unbefallenen, Lymphknoten, was die Metastasierung in diesen Bereichen weiter beg ü nstigt [112,113] . Auch RAGE wurde im Fall von Pankreaskarzinomen mit der F ä higkeit zur Metastasierung assoziiert, wobei von drei Zelllinien mit verschieden hoher Metastasierungsneigung diejenige mit der niedrigsten RAGE-Expression die niedrigste Metastasierungsrate aufwies [114] .…”

Section: Gewebsinfiltration Und Metastasierungunclassified

Immunogene Zelltodmarker HMGB1 und sRAGE als neue prädiktive und prognostische Serum Biomarker bei Tumorerkrankungen/Immunogenic cell death markers HMGB1 and sRAGE as new predictive and prognostic serum biomarkers in cancer disease

Wittwer¹,

Holdenrieder²

2013

Laboratoriumsmedizin

View full text Add to dashboard Cite

ZusammenfassungImmunogene Zelltodmarker sind eine inhomogene Gruppe von Molekülen, die während Zelltodprozessen wie Apoptose, Nekrose oder weiteren Formen freigesetzt werden. Je nach Zusammensetzung des extrazellulären Milieus können diese „Danger associated molecular patterns“ (DAMPs) wie das „High mobility group box 1“ (HMGB1) Protein das Immunsystem stimulierend oder inhibierend beeinflussen. Bei Tumorerkrankungen scheint eine kontinuierliche Freisetzung von HMGB1, u.a. über eine Vermittlung durch den zellulären Bindungspartner „Receptor of advanced glycation end products“ (RAGE), zu einer Förderung des Tumorwachstums zu führen, während die pulsatile Freisetzung während zytotoxischer Therapie zu einer verbesserten antitumorösen Immunantwort beitragen könnte. Lösliches RAGE (sRAGE) kann hingegen die Effekte von extrazellulärem HMGB1 abpuffern. In diesem Review werden die strukturellen und funktionalen Charakteristika dieser immunogenen Zelltodmarker sowie ihre Rolle in der Pathophysiologie von nicht-malignen und malignen Erkrankungen vorgestellt; sodann wird ihre Relevanz als Serum-Biomarker für die Diagnose, die Prognoseabschätzung, die Prädiktion und das Monitoring des Ansprechens einer zytotoxischen Therapie bei Tumorpatienten beleuchtet. Bei Patienten mit verschiedenen Tumorerkrankungen wurden im Vergleich zu gesunden Personen erhöhte Serumkonzentrationen von HMGB1 und niedrigere sRAGE-Werte gefunden. Zudem waren hohe HMGB1- und niedrige sRAGE-Serumwerte vor und während einer zytotoxischen Therapie mit einem unzureichenden Ansprechen auf die Behandlung und einem kürzeren Überleben assoziiert. Diese Ergebnisse weisen die immunogenen Zelltodmarker HMGB1 und sRAGE als neue, vielversprechende Biomarker zur Abschätzung der Prognose, Stratifikation der Patienten und zum Therapiemonitoring bei Tumorpatienten aus.

show abstract

HMGB1 Attenuates Anti-Metastatic Defense of the Lymph Nodes in Colorectal Cancer

Cited by 27 publications

References 64 publications

HMGB1 blockade attenuates experimental autoimmune myocarditis and suppresses Th17‐cell expansion

HMGB1 blockade attenuates experimental autoimmune myocarditis and suppresses Th17‐cell expansion

Effects of HMGB1 expression suppressed by siRNA on cell cycle and proliferation of human cervical cancer cell line HeLa

Immunogene Zelltodmarker HMGB1 und sRAGE als neue prädiktive und prognostische Serum Biomarker bei Tumorerkrankungen/Immunogenic cell death markers HMGB1 and sRAGE as new predictive and prognostic serum biomarkers in cancer disease

Contact Info

Product

Resources

About